Literature summary for 3.4.14.5 extracted from

He, Y.L.; Sabo, R.; Campestrini, J.; Wang, Y.; Ligueros-Saylan, M.; Lasseter, K.C.; Dilzer, S.C.; Howard, D.; Dole, W.P.
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin (2007), Eur. J. Clin. Pharmacol., 63, 677-686.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	there is no significant difference in exposure to vildagliptin in patients with mild, moderate or severe hepatic impairment. Therefore, no dose adjustment of vildagliptin is necessary in patients with hepatic impairment	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
vildagliptin	there is no significant difference in exposure to vildagliptin in patients with mild, moderate or severe hepatic impairment	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
dipeptidyl peptidase IV	-	Homo sapiens
DPP-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)